Navigation Links
ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
Date:11/4/2008

- New Site Provides Extensive Information to Patients and Physicians -

ADDISON, Texas, Nov. 4 /PRNewswire-FirstCall/ -- ULURU Inc. (Amex: ULU) today announced that it has launched a new Altrazeal(TM) website designed to provide information to both health care professionals and patients on the clinical benefits of Altrazeal(TM).

In addition to product information, demonstration of the use of Altrazeal(TM) and product attributes and benefits, the website includes patient testimonials and clinical case studies. As further product information becomes available this will be added to the website including a video of the Satellite Symposium "Altrazeal(TM) - Transforming Clinical Wound Management - From Science to Outcomes with an Innovative Powder Dressing", which was held on October 29, 2008. It is anticipated that this will be available by November 15, 2008.

Altrazeal(TM), a transforming powder dressing, which is produced using our Nanoflex(TM) Technology, is a breakthrough new treatment for exuding wounds including burns, trauma, skin graft donor sites, surgical wounds and chronic slow-healing wounds such as diabetic foot ulcers, pressure ulcers and venous ulcers. Altrazeal(TM) is designed for greater effectiveness in wound closure by promoting an optimal moist wound healing environment. Altrazeal(TM) provides additional patient benefits including reduced pain and enhanced patient comfort, ease of application and removal and, in most cases, it does not require a secondary dressing.

Commenting on the new website, Renaat Van Den Hooff, Executive Vice President Operations of ULURU, stated, "The most important objective of the website is to provide both patients and health care professionals with the most comprehensive and up to date information for obtaining the best clinical results and patient satisfaction with Altrazeal(TM). Also, we plan to add new patient testimonials and clinical case studies that will demonstrate the significant patient benefit being generated by this game-changing new treatment for exuding wounds. By providing this information we believe patient's outcomes will be maximized and the science of treating wounds will continue to advance."

About ULURU Inc.:

ULURU Inc. is an emerging specialty pharmaceutical company focused on the development of a portfolio of wound management, plastic surgery and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at http://www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the response to the product from patients, the importance of use of the product for burn victims, the ability to use the product for chronic wounds, the perception of the product as a transformational innovation in the wound care market, the product accelerates healing and decreases pain and decreases dressing changes. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007, Quarterly Report on Form 10-Q for the quarter ended June 30, 2008 and other reports filed by us with the Securities and Exchange Commission.

Contact: Company Media Contact:

Kerry P. Gray Stephen Zoegall, Ph.D.

President & CEO Berry & Co. Public Relations

Terry K. Wallberg (212) 253-8881

Vice President & CFO szoegall@berrypr.com

(214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
2. ULURU Inc. Announces Poster Presentations at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
3. ULURU Inc. to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors
5. ULURU Inc. Reports First Quarter 2008 Financial Results
6. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
7. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter Ended December 31, 2007 and Provide a Business Update
8. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2008 and Provide a Business Update
9. ULURU Inc. to Present at Cowen and Company 28th Annual Health Care Conference 2008
10. ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent
11. ULURU Inc. Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... ... the Snake”: an entertaining and moral-based short story about an unkind snake learning a ... Jr., a husband, father and grandfather who served as a U.S. Marine, U.S. Army ... for children and teens. My goal is to teach kids to use good judgement ...
(Date:8/17/2017)... NC (PRWEB) , ... August 17, 2017 , ... ... dental practice, is adding a new location in Goldsboro, NC to its family ... care that is Riccobene Associates’ trademark starting August 15, 2017. , Riccobene ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... series, proudly announces that it will feature the National Council for Therapeutic Recreation ... for more information. , Established in 1981, NCTRC is a non-profit, international organization ...
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... will come together on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking ... B. Martin Conference Center at Harvard Medical School. , Industry leaders and decision ...
(Date:8/17/2017)... GA (PRWEB) , ... August 17, 2017 , ... ... to welcome Dr. Kristi Hebert to its newest location in East ... enthusiastic to have Dr. Hebert come aboard,” said Dr. Mark A. Haber, Georgia Urology’s ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... Aug. 2, 2017   Marshall County Hospital in Benton, Kentucky ... the risk of hospital-acquired infections (HAIs). The new addition, Tru-D SmartUVC , short for ... kill deadly pathogens such as C. diff , MRSA, MERS, Ebola and more. ... Tru-D SmartUVC ... Tru-D in action in a patient room ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology: